

Serina Therapeutics co-sponsors symposium on polyoxazoline chemistry

March 26, 2012

FOR IMMEDIATE RELEASE

HUNTSVILLE, Ala. -- Serina Therapeutics, Inc., a pharmaceutical research and development company, announced today it will co-sponsor a three-day symposium at the American Chemical Society (ACS) National Meeting in San Diego. The symposium, "Poly(2-oxazolines) and related pseudo-polypeptide structures," will be held at the Manchester Grand Hyatt on March 27– 29.

This symposium will bring together over 50 academic and industry speakers from Europe and the Americas. They will share a wealth of knowledge on the chemistry, properties and medical applications of this novel biopolymer. "The strong interest in polyoxazoline is not surprising," said Michael D. Bentley, Ph.D., chief scientific officer and cofounder of the company. "As pharmaceuticals become more complex – particularly those that are difficult to deliver by standard routes-- we should see a growing interest in the use of polyoxazoline in medicine."

About Serina

Serina Therapeutics is a privately held pharmaceutical company that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled nine approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit <http://www.serinatherapeutics.com>